What is your approach to the decision to use CPX-351 or standard 7+3 for de novo AML?

Do you await molecular and cytogenetic results prior to initiating therapy, or does age and function status primarily drive your choice?

Answer from: Medical Oncologist at Academic Institution

CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. It was approved by the FDA in 2017 for the treatment of adults with newly-diagnosed therapy-related acute my...

Comments

Medical Oncologist at Texas Oncology
What are you doing to temporize while awaiting mol...

Answer from: Medical Oncologist at Community Practice

We typically temporize with supportive care/hydrea and get the relevant data back within a week.

Comments

Medical Oncologist at University of Virginia
What is your approach when deciding CPX-351 versus...

Please select the option that best describes you:

What is your approach to the decision to use CPX-351 or standard 7+3 for de novo AML?

Related Questions